Warren Buffett Stocks: What’s in Berkshire Hathaway’s Portfolio?
You should keep an eye on Warren Buffett stocks because, while the Berkshire Hathaway (BRKB) CEO adheres to a proven investment strategy, he isn’t content to stay quiet.
Berkshire Hathaway Sells Drug Stocks Again and Purchases Royalty Pharma
For the fourth consecutive quarter, Berkshire Hathaway was a net seller of equities in the third quarter. According to a 13F filing on Nov. 15, the conglomerate purchased Royalty Pharma (RPRX) and Floor & Decor (FND) for the first time in Q3. Royalty Pharma provides investors with exposure to volatile biotech firms without exposing them to significant drug development risks.
Buffett’s Berkshire Hathaway departed Merck (MRK) and Merck spinoff Organon (OGN). It reduced its stakes in AbbVie (ABBV) and Bristol-Myers Squibb (BMY) even more after purchasing them for the first time in Q3 2020.
Buffett increased his holdings in Chevron (CVX) while decreasing his holdings in Visa (V) and Mastercard (MA) (MA).
Earlier in the quarter, Berkshire reduced its holdings of different pharmaceuticals while exiting Biogen (BIIB).
Buffett, on the other hand, increased his holdings in consumer firms such as Kroger (KR) and luxury furnishings retailer RH (RH) in the second quarter, while also…
